| Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, ... Nature 602 (7898), 664-670, 2022 | 1112 | 2022 |
| Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab A Gupta, Y Gonzalez-Rojas, E Juarez, M Crespo Casal, J Moya, DR Falci, ... New England Journal of Medicine 385 (21), 1941-1950, 2021 | 1063 | 2021 |
| Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity CM Hebner, LA Laimins Reviews in medical virology 16 (2), 83-97, 2006 | 534 | 2006 |
| SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape TN Starr, N Czudnochowski, Z Liu, F Zatta, YJ Park, A Addetia, D Pinto, ... Nature 597 (7874), 97-102, 2021 | 380 | 2021 |
| Infrequent development of resistance in genotype 1–6 hepatitis C virus–infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials ES Svarovskaia, H Dvory-Sobol, N Parkin, C Hebner, V Gontcharova, ... Clinical Infectious Diseases 59 (12), 1666-1674, 2014 | 248 | 2014 |
| The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma, MA Schmid, ... biorxiv, 2021.03. 09.434607, 2021 | 207 | 2021 |
| Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation MLG Lamm, WS Catbagan, RJ Laciak, DH Barnett, CM Hebner, ... Developmental biology 249 (2), 349-366, 2002 | 182 | 2002 |
| Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures C Hebner, VM Weaver, J Debnath Annu. Rev. Pathol. Mech. Dis. 3, 313-339, 2008 | 175 | 2008 |
| Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate MLG Lamm, CA Podlasek, DH Barnett, J Lee, JQ Clemens, CM Hebner, ... Developmental biology 232 (2), 301-314, 2001 | 167 | 2001 |
| Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial M Rodriguez-Torres, E Lawitz, KV Kowdley, DR Nelson, E DeJesus, ... Journal of hepatology 58 (4), 663-668, 2013 | 133 | 2013 |
| Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody S Chandramouli, C Ciferri, PA Nikitin, S Caló, R Gerrein, K Balabanis, ... Nature communications 6 (1), 8176, 2015 | 117 | 2015 |
| Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase I Shih, I Vliegen, B Peng, H Yang, C Hebner, J Paeshuyse, G Pürstinger, ... Antimicrobial Agents and Chemotherapy 55 (9), 4196-4203, 2011 | 108 | 2011 |
| Compositions and methods for treating hepatitis C virus DG Cleary, CJ Reynolds, MM Berrey, RG Hindes, WT Symonds, AS Ray, ... US Patent 8,889,159, 2014 | 107 | 2014 |
| Human papillomaviruses target the double-stranded RNA protein kinase pathway CM Hebner, R Wilson, J Rader, M Bidder, LA Laimins Journal of general virology 87 (11), 3183-3193, 2006 | 76 | 2006 |
| Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation C Hebner, M Beglin, LA Laimins Journal of virology 81 (23), 12740-12747, 2007 | 61 | 2007 |
| The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function CM Hebner, B Han, KM Brendza, M Nash, M Sulfab, Y Tian, M Hung, ... PLoS One 7 (6), e39163, 2012 | 50 | 2012 |
| Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa KM Krause, CM Haglund, C Hebner, AW Serio, G Lee, V Nieto, F Cohen, ... Antimicrobial agents and chemotherapy 63 (11), 10.1128/aac. 00977-19, 2019 | 44 | 2019 |
| Compositions and methods for treating hepatitis C virus DG Cleary, CJ Reynolds, MM Berrey, RG Hindes, WT Symonds, AS Ray, ... US Patent 9,549,941, 2017 | 34 | 2017 |
| In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539 HD Patel, P Nikitin, T Gesner, JJ Lin, DT Barkan, C Ciferri, A Carfi, ... Antimicrobial agents and chemotherapy 60 (8), 4961-4971, 2016 | 34 | 2016 |
| Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat Commun 6: 8176 S Chandramouli, C Ciferri, PA Nikitin, S Calo, R Gerrein, K Balabanis, ... | 27 | 2015 |
